1813-24-7

Usage

Uses

Used in Chemical Research:
5-Methyl-2-nitro-4-trifluoromethyl-phenylamine is used as a research compound for studying its chemical properties and reactions, contributing to the understanding of aniline derivatives and their potential applications.
Used in Pharmaceutical Development:
MNTFM-Phenylamine is used as an intermediate in the synthesis of pharmaceutical compounds, leveraging its unique functional groups to create new drugs with specific therapeutic properties.
Used in Medicinal Chemistry:
5-Methyl-2-nitro-4-trifluoromethyl-phenylamine is used as a building block in the design and development of novel therapeutic agents, potentially leading to the discovery of new drugs with improved efficacy and safety profiles.
Used in Materials Science:
MNTFM-Phenylamine is used in the development of new materials with specific properties, such as high thermal stability or unique electronic characteristics, by incorporating its structural features into the material's composition.

Upstream product

• 35375-74-7 5-chloro-2-nitro-4-(trifluoromethyl)aniline 
• 105-53-3 diethyl malonate 
• 13630-15-4 1-Chlor-3-methyl-4-trichlormethyl-benzol 
• 13630-22-3 4-chloro-2-methyl-1-(trifluoromethyl)benzene 
• 3274-12-2 4-methyl-4-(trichloromethyl)cyclohexa-2,5-dien-1-one 
• 18018-35-4 1-chloro-5-methyl-2-nitro-4-(trifluoromethyl)benzene 

Downstream Products

• 871571-25-4 1-bromo-5-methyl-2-nitro-4-trifluoromethyl-benzene 
• 320-37-6 4-nitro-2-(trifluoromethyl)benzoic acid 
• 1737-64-0 4,5-Diamino-2-trifluormethyl-toluol 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 

Relevant academic research and scientific papers

Novel compounds as metabotropic glutamate receptor antagonists

The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.

Pyrrazolo-pyrimidine derivatives

The present invention relates to pyrrazolo-pyrimidine derivatives of formula (I): wherein R1 to R4 and A are as defined in the specification, a process for the manufacture thereof, their use for treating or preventing metabotropic glutamate receptors mediated disorders, their use for the preparation of medicaments for treating such disorders and pharmaceutical compositions containing said derivatives.

Acetylenyl-pyrazolo-pyrimidine derivatives

The present invention relates to compounds of formula (I): wherein R1 to R3, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

PYRRAZOLO-PYRIMIDINE DERIVATIVES

The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as ph